<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01751776</url>
  </required_header>
  <id_info>
    <org_study_id>1293.2</org_study_id>
    <secondary_id>2012-004090-16</secondary_id>
    <nct_id>NCT01751776</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Netherlands: Central Committee Research Involving Human Subjects</authority>
    <authority>New Zealand: Medsafe</authority>
    <authority>Poland: Registration Medicinal Product Medical Device Biocidal Product</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of multiple doses of BI 655064 administered
      subcutaneously in healthy volunteers (HVs) and in rheumatoid arthritis (RA) patients. To
      explore the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of multiple doses of BI
      655604 in  healthy volunteers (HVs) and rheumatoid arthritis (RA) patients. To assess
      clinical effect of BI 655604 in RA patients with prior inadequate response to methotrexate
      (MTX) after 12 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary PK endpoint (Part 1): Cmax (after first and 4th dose)</measure>
    <time_frame>up to Day 64 post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary PK endpoint (Part 1): AUC 0-infinity (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinite)</measure>
    <time_frame>Up to Day 64 post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary PK endpoint (Part 1): AUC t,4 (Area under the concentration-time curve of the analyte in plasma after the 4th dose over a uniform dosing interval t) after the first and 4th dose)</measure>
    <time_frame>Up to Day 64 post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with drug related Adverse Events (Part 1).</measure>
    <time_frame>Up to Day 64 post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 (American College of Rheumatology) response rate at week 12 (day 85) from the initiation of study treatment (Part 2)</measure>
    <time_frame>week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR50 and 70 response rates at week 12 (day 85) (Part 2)</measure>
    <time_frame>week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR (European League Against Rheumatism) response criteria measured as the disease activity score with four variables including c-reactive protein (DAS28 4v-CRP) at week 12 (day 85) (Part 2)</measure>
    <time_frame>week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a decrease in DAS28 4v-CRP of &gt;1.2 at week 12 (day 85) compared to baseline (Part 2)</measure>
    <time_frame>baseline and week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 655064 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 different doses plus placebo in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 655064 Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 different doses plus placebo in rheumatoid arthritis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064 medium dose</intervention_name>
    <description>Medium dose</description>
    <arm_group_label>BI 655064 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064 high dose</intervention_name>
    <description>High dose</description>
    <arm_group_label>BI 655064 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064 high dose</intervention_name>
    <description>High dose</description>
    <arm_group_label>BI 655064 Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BI 655064 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064 low dose</intervention_name>
    <description>Low dose</description>
    <arm_group_label>BI 655064 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BI 655064 Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064 medium dose</intervention_name>
    <description>Medium dose</description>
    <arm_group_label>BI 655064 Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy Volunteers (HVs) in Part 1:

          1. Healthy males and females according to the investigator¿s assessment (females of
             child-bearing potential must be using effective contraception)

          2. Age 18 - 60 years

          3. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Rheumatoid Arthritis (RA) patients in Part 2:

          1. Age 18 - 70 years

          2. Classified as having RA according to the 1987 American College of Rheumatology (ACR)
             Classification Criteria

          3. &lt;5 years from RA diagnosis to screening

          4. Inadequate clinical response to methotrexate (MTX) monotherapy defined as
             moderate/high active disease after oral or subcutaneous (s.c.) MTX treatment given
             continuously for at least 3 months and for the last 6 weeks before screening at a
             stable weekly dose &gt;15mg.

          5. DAS28 4v-CRP &gt;3.5 with &gt;6 tender and &gt;6 swollen joints at screening and confirmed by
             &gt;6 tender and &gt;6 swollen joints at randomisation visit (Visit 2)

          6. Serum CRP level =1.0 mg/dL at screening

          7. Anti-CCP2 positivity according to the limits of the assay used

          8. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

        Healthy Volunteers (HVs) in Part 1:

        1. Any finding on clinical examination/history or laboratory value which deviates from
        normality and has clinical significance

        Rheumatiod Arthritis (RA) pts in Part 2:

        1. Current or previous use of an approved biologic agent 2. Current or previous
        participation in a clinical trial testing an investigational drug for RA 3. Disease
        activity score (DAS)28 &lt; 3.2 in at least 2 occasions during the last 6 months before
        screening 4. Treatment with any standard disease modifying anti-rheumatic drug (DMARD)
        except methotrexate (MTX) continuing after randomisation 5. RA patients with severe
        disability (functional class IV) or with confirmed severe systemic manifestations 6.
        Impaired hepatic or renal function 8. Pre-existing blood dyscrasias 9. Hypersensitivity to
        MTX or any of its excipients 10. Previous intolerance to MTX as the main cause for
        stopping treatment (instead of lack of efficacy) 11. Any active or suspected malignancy or
        history of documented malignancy, except appropriately 12. Chronic or relevant acute
        infections, including but not limited to HIV, Hepatitis B and C and tuberculosis
        (including a history of clinical TB and/or a positive QuantiFERON TB-Gold test) treated
        basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.

        13. Subject is assessed by the investigator as unsuitable for inclusion e.g. considered
        not able to understand and comply with study requirements or has a condition that would
        not allow safe participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1293.2.00030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hostivice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Kreuznach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zerbst</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grafton Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Palmar - Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Laguna (Sta Cruz Tenerife)</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1293.2.00020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
